About the Study

Primary Mediastinal B-cell lymphoma (PMBCL): A study combining nivolumab and chemo-immunotherapy as a treatment option

This study is for children: • 2 years old and older • Received a diagnosis of primary mediastinal B-cell lymphoma (PMBCL) The goal of this study is to compare the effects, good and/or bad, of nivolumab with chemo-immunotherapy versus chemo-immunotherapy alone. In this study children will get 1 of 2 treatment plans.

Interested in learning more?

Full Study Name: ANHL1931 - A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma